OncoMatch/Clinical Trials/NCT04535271
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
Is NCT04535271 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trabectedin for leiomyosarcoma.
Treatment: Trabectedin — This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC >1000 cells/μL; Platelet count >100,000/μL; Hemoglobin > 9.0 g/dL
Kidney function
Creatinine < 1.5 x ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula
Liver function
Bilirubin < 1.5 x ULN (except Gilbert Syndrome < 3.0 x ULN); AST, ALT, alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present)
Acceptable liver function: Bilirubin < 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level < 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos < 2.5 x ULN (< 5 x ULN if liver metastases present) Acceptable renal function: Creatinine < 1.5 times ULN and creatinine clearance > 60 ml/min using the Crockroft-Gault formula Acceptable hematologic status: ANC >1000 cells/μL; Platelet count >100,000/μL; Hemoglobin > 9.0 g/dL INR and PT < 1.5 ULN unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sant P Chawla · Santa Monica, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify